212 related articles for article (PubMed ID: 35460976)
1. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
2. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
3. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
[TBL] [Abstract][Full Text] [Related]
4. Desmoid Tumors: Current Perspective and Treatment.
Mangla A; Agarwal N; Schwartz G
Curr Treat Options Oncol; 2024 Feb; 25(2):161-175. PubMed ID: 38270798
[TBL] [Abstract][Full Text] [Related]
5. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
6. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
Wang Z; Wu J; Tian X; Hao C
Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
[TBL] [Abstract][Full Text] [Related]
8. Desmoid: the role of local therapy in an era of systemic options.
Walczak BE; Rose PS
Curr Treat Options Oncol; 2013 Sep; 14(3):465-73. PubMed ID: 23760919
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
10. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
[TBL] [Abstract][Full Text] [Related]
11. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
12. Optimal therapy for desmoid tumors: current options and challenges for the future.
Al-Jazrawe M; Au M; Alman B
Expert Rev Anticancer Ther; 2015; 15(12):1443-58. PubMed ID: 26472625
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
Downie EM; Amend CE; Miranda A; Burkat CN
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
[TBL] [Abstract][Full Text] [Related]
14. Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option.
Sari M
J Cancer Res Ther; 2020; 16(4):900-902. PubMed ID: 32930137
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
McLean TD; Duchi S; Di Bella C
Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).
de Camargo VP; Keohan ML; D'Adamo DR; Antonescu CR; Brennan MF; Singer S; Ahn LS; Maki RG
Cancer; 2010 May; 116(9):2258-65. PubMed ID: 20187095
[TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE
PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
19. PROMIS Function Scores Are Lower in Patients Who Underwent More Aggressive Local Treatment for Desmoid Tumors.
Newman ET; Lans J; Kim J; Ferrone M; Ready J; Schwab J; Raskin K; Calderon SL
Clin Orthop Relat Res; 2020 Mar; 478(3):563-577. PubMed ID: 31429829
[TBL] [Abstract][Full Text] [Related]
20. Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Gounder MM; Lefkowitz RA; Keohan ML; D'Adamo DR; Hameed M; Antonescu CR; Singer S; Stout K; Ahn L; Maki RG
Clin Cancer Res; 2011 Jun; 17(12):4082-90. PubMed ID: 21447727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]